FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Che	ck this box if no longer subject to
Sect	ion 16. Form 4 or Form 5
oblig	ations may continue. See
Instr	uction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 19	3
or Section 30(h) of the Investment Company Act of 1940	

Name and Address of Reporting Person* KREHER NERISSA (Last) (First) (Middle)							Issuer Name and Ticker or Trading Symbol Entrada Therapeutics, Inc. [TRDA] Joace of Earliest Transaction (Month/Day/Year)									able) r (give title		10% Ow Other (s below)	ner
C/O ENTRADA THERAPEUTICS, INC. 6 TIDE STREET					03/	03/01/2022									Chief Medical Officer				
(Street) BOSTON MA 02210					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	′				
(City)	(S	tate)	(Zip)																
		Tab	le I - Nor	ı-Deriv	vativ	e Se	curities	s Ac	quired,	Dis	posed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3) 2. Trans Date (Month/						ction 2A. Deemed Execution Date, if any (Month/Day/Year)			Code (I	Transaction Disposed Of (D) (Instr. Code (Instr. 5)			ed (A) o str. 3, 4	or and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	Amount	(A) or (D)		ce	Transact (Instr. 3	action(s)							
Common Stock 03/01						/2022		A		10,344	4 ⁽¹⁾ A		SO ⁽¹⁾	15,	15,544		D		
		-	Table II -								osed of, onverti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code (l 8)		of		6. Date Exercisable Expiration Date (Month/Day/Year)		•	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		[B. Price of Derivative Security Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amou or Numl of Share	oer					
Stock Option (Right to Buy)	\$11.57	03/01/2022			A		62,063		(2)	C	03/01/2032	Common stock	62,0	63	\$0	62,06	3	D	

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

2. 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

03/03/2022 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.